Company intelligence / Profile preview

OutSense

Ownership: Private
Development stage: Other

Overview

OutSense’s platform has demonstrated a 90% accuracy rate for blood detection compared to gold-standard diagnostics, with an AUC of 88.20%. The technology is being piloted with major healthcare providers and elderly care institutions, including clinical trials in Israel and pilots in the US and Japan. It enables real-time alerts for early disease detection directly from toilet-based sensors without manual sample collection.

Therapeutic areas: Infectious DiseasesGastroenterologyMetabolic DisordersOncology
Modalities: DeviceNon-pharmacological therapy (diagnostic)
Industry: Physiological Monitoring

Partnerships

Longevity Venture Partners/CommuniCare Family of Companies (pilot partner)

Beyond the preview

Go deeper on OutSense.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OutSense.

Explore the full profile